BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vitiello A, Ferrara F. Anti-fibrotic therapy for the treatment of pulmonary sequelae in patients healed by COVID-19. Lung India 2021;38:S129-30. [PMID: 33687000 DOI: 10.4103/lungindia.lungindia_803_20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Ferrara F, Vitiello A. The renin-angiotensin system and specifically angiotensin-converting enzyme 2 as a potential therapeutic target in SARS-CoV-2 infections. Naunyn Schmiedebergs Arch Pharmacol 2021;394:1589-93. [PMID: 34151392 DOI: 10.1007/s00210-021-02108-z] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
2 Vitiello A, Ferrara F. Risk of drug-induced cardiac arrhythmia during COVID-19 therapeutic treatment. Egypt Heart J 2021;73:103. [PMID: 34792677 DOI: 10.1186/s43044-021-00228-8] [Reference Citation Analysis]
3 Vitiello A, Ferrara F, Troiano V, La Porta R. COVID-19 vaccines and decreased transmission of SARS-CoV-2. Inflammopharmacology 2021. [PMID: 34279767 DOI: 10.1007/s10787-021-00847-2] [Reference Citation Analysis]
4 Vitiello A, Ferrara F. Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients. Curr Res Pharmacol Drug Discov 2021;2:100056. [PMID: 34870154 DOI: 10.1016/j.crphar.2021.100056] [Reference Citation Analysis]
5 Vitiello A, Ferrara F. Low Molecular Weight Heparin, Anti-inflammatory/Immunoregulatory and Antiviral Effects, a Short Update. Cardiovasc Drugs Ther 2021. [PMID: 34460031 DOI: 10.1007/s10557-021-07251-6] [Reference Citation Analysis]